Neurocrine Biosciences Inc (NBIX)vsTeva Pharma Industries Ltd ADR (TEVA)
NBIX
Neurocrine Biosciences Inc
$127.68
-1.56%
HEALTHCARE · Cap: $13.12B
TEVA
Teva Pharma Industries Ltd ADR
$28.73
-2.41%
HEALTHCARE · Cap: $34.31B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates 503% more annual revenue ($17.26B vs $2.86B). NBIX leads profitability with a 16.7% profit margin vs 8.2%. NBIX appears more attractively valued with a PEG of 0.27. NBIX earns a higher WallStSmart Score of 75/100 (B+).
NBIX
Strong Buy75
out of 100
Grade: B+
TEVA
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+37.1%
Fair Value
$218.56
Current Price
$127.68
$90.88 discount
Margin of Safety
+39.4%
Fair Value
$56.63
Current Price
$28.73
$27.90 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Strong operational efficiency at 28.2%
Revenue surging 28.3% year-over-year
Earnings expanding 47.7% YoY
Every $100 of equity generates 21 in profit
Strong operational efficiency at 27.3%
Earnings expanding 40.0% YoY
Generating 1.0B in free cash flow
Areas to Watch
Moderate valuation
Weak financial health signals
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : NBIX
The strongest argument for NBIX centers on PEG Ratio, Altman Z-Score, Debt/Equity. Profitability is solid with margins at 16.7% and operating margin at 28.2%. Revenue growth of 28.3% demonstrates continued momentum.
Bull Case : TEVA
The strongest argument for TEVA centers on Return on Equity, Operating Margin, EPS Growth. Revenue growth of 11.4% demonstrates continued momentum. PEG of 1.47 suggests the stock is reasonably priced for its growth.
Bear Case : NBIX
The primary concerns for NBIX are P/E Ratio, Piotroski F-Score.
Bear Case : TEVA
The primary concerns for TEVA are Altman Z-Score.
Key Dynamics to Monitor
NBIX profiles as a growth stock while TEVA is a value play — different risk/reward profiles.
TEVA carries more volatility with a beta of 0.72 — expect wider price swings.
NBIX is growing revenue faster at 28.3% — sustainability is the question.
TEVA generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
NBIX scores higher overall (75/100 vs 73/100), backed by strong 16.7% margins and 28.3% revenue growth. TEVA offers better value entry with a 39.4% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Neurocrine Biosciences Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric diseases and disorders in the United States. The company is headquartered in San Diego, California.
Visit Website →Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?